CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Sees Significant Growth in Short Interest

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 131,118 shares, a growth of 498.5% from the August 15th total of 21,907 shares. Based on an average daily trading volume, of 17,402,039 shares, the short-interest ratio is presently 0.0 days. Approximately 10.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. increased its position in CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 557,193 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Pinnacle Associates Ltd. owned about 4.36% of CollPlant Biotechnologies worth $780,000 at the end of the most recent reporting period. 21.69% of the stock is currently owned by institutional investors.

CollPlant Biotechnologies Price Performance

NASDAQ:CLGN opened at $3.54 on Friday. CollPlant Biotechnologies has a 12-month low of $2.64 and a 12-month high of $31.80. The firm has a market capitalization of $5.10 million, a P/E ratio of -0.24 and a beta of 1.79. The business has a 50 day simple moving average of $3.32 and a 200 day simple moving average of $4.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Friday, September 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $120.00.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.